SG11202109024YA - Tricyclic degraders of ikaros and aiolos - Google Patents
Tricyclic degraders of ikaros and aiolosInfo
- Publication number
- SG11202109024YA SG11202109024YA SG11202109024YA SG11202109024YA SG11202109024YA SG 11202109024Y A SG11202109024Y A SG 11202109024YA SG 11202109024Y A SG11202109024Y A SG 11202109024YA SG 11202109024Y A SG11202109024Y A SG 11202109024YA SG 11202109024Y A SG11202109024Y A SG 11202109024YA
- Authority
- SG
- Singapore
- Prior art keywords
- aiolos
- ikaros
- degraders
- tricyclic
- tricyclic degraders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833107P | 2019-04-12 | 2019-04-12 | |
| PCT/US2020/027678 WO2020210630A1 (en) | 2019-04-12 | 2020-04-10 | Tricyclic degraders of ikaros and aiolos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109024YA true SG11202109024YA (en) | 2021-09-29 |
Family
ID=72750851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109024YA SG11202109024YA (en) | 2019-04-12 | 2020-04-10 | Tricyclic degraders of ikaros and aiolos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11407732B1 (en) |
| EP (1) | EP3953332A4 (en) |
| JP (1) | JP2022527216A (en) |
| KR (1) | KR20210152515A (en) |
| CN (1) | CN113677664A (en) |
| AU (1) | AU2020272978A1 (en) |
| BR (1) | BR112021019669A2 (en) |
| CA (1) | CA3130469A1 (en) |
| EA (1) | EA202192738A1 (en) |
| IL (1) | IL287116A (en) |
| MA (1) | MA55628A (en) |
| MX (1) | MX2021012524A (en) |
| SG (1) | SG11202109024YA (en) |
| WO (1) | WO2020210630A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118108706A (en) | 2017-09-04 | 2024-05-31 | C4医药公司 | Glutarimide |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | Dihydroquinolinones |
| US11319330B2 (en) * | 2018-09-07 | 2022-05-03 | Medshine Discovery Inc. | Tricyclic furan-substituted piperidinedione compound |
| JP2023509375A (en) | 2019-12-20 | 2023-03-08 | シーフォー セラピューティクス， インコーポレイテッド | Isoindolinone and indazole compounds for the degradation of EGFR |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| BR112022017393A2 (en) | 2020-03-05 | 2022-10-18 | C4 Therapeutics Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD TO TREAT A BRD9-mediated DISORDER, AND, USE OF A COMPOUND |
| CA3173658A1 (en) * | 2020-08-07 | 2022-02-10 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by ikaros or aiolos |
| WO2022081928A1 (en) * | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic heterobifunctional compounds for degradation of targeted proteins |
| AU2021361043A1 (en) * | 2020-10-14 | 2023-06-08 | C4 Therapeutics, Inc. | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
| WO2022235945A1 (en) | 2021-05-05 | 2022-11-10 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
| BR112023023223A2 (en) | 2021-05-07 | 2024-01-30 | Kymera Therapeutics Inc | CDK2 DEGRADERS AND USES THEREOF |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| MX2024000395A (en) | 2021-07-07 | 2024-04-05 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins. |
| WO2023283372A1 (en) | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| EP4393915A1 (en) * | 2021-08-27 | 2024-07-03 | Hangzhou Glubio Pharmaceutical Co. Ltd. | Isoindolinone compound and use thereof |
| TW202322799A (en) * | 2021-10-06 | 2023-06-16 | 美商Ｃ４醫藥公司 | Coronavirus non-structural protein 3 degrading compounds |
| WO2023061478A1 (en) * | 2021-10-15 | 2023-04-20 | 先声再明医药有限公司 | Tricyclic compound |
| KR20240146048A (en) * | 2022-02-09 | 2024-10-07 | 씨4 테라퓨틱스, 인코포레이티드 | Morphological form of CFT7455 and its preparation method |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN116120261B (en) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound |
| WO2024193641A1 (en) * | 2023-03-21 | 2024-09-26 | 上海超阳药业有限公司 | Isoindoline derivative, benzoindole derivative and use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| ES2426350T3 (en) | 2006-08-30 | 2013-10-22 | Celgene Corporation | Isoindoline compounds substituted in 5 |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CL2007002670A1 (en) | 2006-09-15 | 2008-05-16 | Celgene Corp Soc Organizada Ba | COMPOUNDS DERIVED FROM N-METHYLAMINEOME-ISOINDOLINE; PHARMACEUTICAL COMPOSITION; DOSAGE FORM, USEFUL TO TREAT OR PREVENT DISEASES SUCH AS CANCER, PAIN, PULMONARY DISORDER, CNS DISORDER AND ATEROSCLEROSIS. |
| MX2009003038A (en) | 2006-09-26 | 2009-04-15 | Celgene Corp | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same. |
| ES2601131T3 (en) | 2007-03-20 | 2017-02-14 | Celgene Corporation | 4'-O-substituted isoindoline derivatives and compositions comprising them and methods of use thereof |
| SG176442A1 (en) | 2007-09-26 | 2011-12-29 | Celgene Corp | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| WO2009139880A1 (en) | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
| PL2358697T3 (en) | 2008-10-29 | 2016-04-29 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer. |
| WO2012175481A1 (en) | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
| MX358660B (en) | 2012-01-12 | 2018-08-30 | Univ Yale | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase. |
| MX2016007239A (en) | 2013-12-06 | 2017-01-05 | Celgene Corp | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers. |
| CN111662226B (en) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 2-oxo-1, 2-dihydrobenzo [ cd ] indole compound |
| DK3404024T3 (en) | 2016-01-14 | 2021-01-11 | Kangpu Biopharmaceuticals Inc | QUINAZOLINE DERIVATIVE, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USES |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| PL3527210T3 (en) | 2016-12-16 | 2021-11-29 | Kangpu Biopharmaceuticals, Ltd. | Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof |
| CN110248662B (en) | 2017-02-13 | 2022-08-16 | 康朴生物医药技术（上海）有限公司 | Combination, pharmaceutical composition and treatment method for treating prostate cancer |
| EP3590924B1 (en) | 2017-02-28 | 2021-10-27 | Kangpu Biopharmaceuticals, Ltd. | Novel isoindoline derivative, and pharmaceutical composition and application thereof |
| JP7258009B2 (en) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | Antiproliferative compounds and methods of use thereof |
| TWI793151B (en) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CA3101338A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
| US20210284624A1 (en) | 2018-06-29 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| AU2019294836B2 (en) | 2018-06-29 | 2024-06-20 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| EP3813834A4 (en) | 2018-06-29 | 2022-03-09 | Dana Farber Cancer Institute, Inc. | New crbn modulators |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US20220348556A1 (en) | 2018-07-06 | 2022-11-03 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| DK3820573T3 (en) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES |
| WO2021041664A1 (en) | 2019-08-27 | 2021-03-04 | The Regents Of The University Of Michigan | Cereblon e3 ligase inhibitors |
| CN116194453A (en) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | Protein tyrosine phosphatase degrading agent and method of use thereof |
-
2020
- 2020-04-10 SG SG11202109024YA patent/SG11202109024YA/en unknown
- 2020-04-10 MX MX2021012524A patent/MX2021012524A/en unknown
- 2020-04-10 EA EA202192738A patent/EA202192738A1/en unknown
- 2020-04-10 CA CA3130469A patent/CA3130469A1/en active Pending
- 2020-04-10 EP EP20788335.6A patent/EP3953332A4/en active Pending
- 2020-04-10 JP JP2021559999A patent/JP2022527216A/en active Pending
- 2020-04-10 MA MA055628A patent/MA55628A/en unknown
- 2020-04-10 CN CN202080028010.XA patent/CN113677664A/en active Pending
- 2020-04-10 WO PCT/US2020/027678 patent/WO2020210630A1/en active Application Filing
- 2020-04-10 BR BR112021019669A patent/BR112021019669A2/en unknown
- 2020-04-10 AU AU2020272978A patent/AU2020272978A1/en active Pending
- 2020-04-10 KR KR1020217036582A patent/KR20210152515A/en unknown
-
2021
- 2021-10-10 IL IL287116A patent/IL287116A/en unknown
- 2021-10-11 US US17/498,617 patent/US11407732B1/en active Active
-
2022
- 2022-04-18 US US17/723,199 patent/US20230082430A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527216A (en) | 2022-05-31 |
| CA3130469A1 (en) | 2020-10-15 |
| EA202192738A1 (en) | 2022-03-17 |
| CN113677664A (en) | 2021-11-19 |
| US20230082430A1 (en) | 2023-03-16 |
| KR20210152515A (en) | 2021-12-15 |
| MX2021012524A (en) | 2021-11-12 |
| WO2020210630A1 (en) | 2020-10-15 |
| EP3953332A1 (en) | 2022-02-16 |
| BR112021019669A2 (en) | 2021-12-07 |
| AU2020272978A1 (en) | 2021-09-16 |
| EP3953332A4 (en) | 2023-06-14 |
| IL287116A (en) | 2021-12-01 |
| MA55628A (en) | 2022-02-16 |
| US11407732B1 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287116A (en) | Tricyclic degraders of ikaros and aiolos | |
| IL283471A (en) | Irak degraders and uses thereof | |
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| IL277729A (en) | Modulators of proteolysis and associated methods of use | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL289813A (en) | Anti-tau antibody and use of same | |
| IL268112A (en) | Anti-tgf-beta antibodies and their use | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| KR102116512B9 (en) | - colorless and transparent polyamide-imide flim and preparation method of the same | |
| SG11202106498XA (en) | Anti-ctla4 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| IL287282A (en) | Anti-mertk antibodies and their methods of use | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| EP3803976C0 (en) | Led display structures and fabrication of same | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| IL288886A (en) | Antibodies and methods of use | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof |